In addition to exploring science by testing molecules in our disease-relevant assays, we also seek specific partnerships and collaborations. We are using PPI (protein-protein interaction) technology to produce the next class of small molecules that work like biologics but can be delivered orally for patients with inflammatory skin diseases. Specifically, we are now exploring partnerships related to PPI technologies using our two specific assays targeting the IL4-Receptor and STAT6. We invite you test your molecules for the ability to inhibit the protein-protein interactions of those targets.